| Patient | Geronimo |
|---|---|
| Date of birth | 1829-06-01 |
| Identifiers | MRN HR-NI016-SYN-TD; SSN (made up) 000-16-4729 |
| Document date | 1906-08-19 |
| Author | Roberta Whitehorse-Lindgren, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review: therapy, naltrexone, sleep and mood. [S]
Geronimo returns six weeks after intake, with the interpreter. He has had four sessions of cognitive processing therapy and says the therapist listens and does not push him to speak of what he will not. He drinks on two evenings a week, two drinks each time, and has had no nausea on naltrexone. The nightmares still come about four nights a week and he sleeps four or five hours. He asks whether a medicine could help him sleep and lift the heaviness. Sertraline was explained, with its side effects and the sodium check, and prazosin for nightmares was discussed: he chose sertraline at a low dose and agreed to wait on prazosin because of his fall. [S]
| Element | Detail |
|---|---|
| Therapy | Four of twelve sessions |
| Drinking | Two evenings a week, two drinks each |
| PCL-5 | 46 |
| PHQ-9 | 10, item 9 scored 0 |
| Liver tests | AST 41, ALT 31, GGT 84 U/L |
| System | Result | Finding |
|---|---|---|
| Psychiatric | Positive | Nightmares four nights a week; mood heavy; no thoughts of suicide |
| Gastrointestinal | Negative | No nausea or abdominal pain on naltrexone |
| Neurological | Negative | No dizziness on standing |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Thiamine 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1906-07-08 | active | S |
| Naltrexone 50 mg oral tablet, one tablet daily; carries a wallet card saying that naltrexone blocks opioid pain medicines | One tablet daily | Oral route | 1906-07-22 | active | S |
| Sertraline 25 mg oral tablet, one tablet each morning, raised to 50 mg after the sodium check | One tablet each morning | Oral route | 1906-08-19 to 1906-09-23 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1906-08-19 | Body height | 173 | cm | S |
| 1906-08-19 | Body weight | 66.8 | kg | S |
| 1906-08-19 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 1906-08-19 | Systolic blood pressure | 132 | mm[Hg] | S |
| 1906-08-19 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1906-08-19 | Heart rate | 74 | /min | S |
| 1906-08-19 | Respiratory rate | 16 | /min | S |
| 1906-08-19 | Body temperature | 36.6 | Cel | S |
| 1906-08-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1906-08-19 | PTSD PCL-5 score [PCL-5] | 46 | {score} | S | ||
| 1906-08-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 10 | {score} | S | ||
| 1906-08-19 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 10-40 U/L | High | S |
| 1906-08-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-56 U/L | Normal | S |
| 1906-08-19 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 84 | U/L | 8-61 U/L | High | S |
Vital signs recorded on 1906-08-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 132/78 seated and 130/76 standing; pulse 74; weight 66.8 kg |
| Mental status | Calm; more eye contact; mood heavy; no thoughts of suicide or of harming anyone |
| Gait | Steady; Timed Up and Go 12 seconds |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Poor sleep for many years with nightmares and unwanted memories of past violence, worse over the past year; drinks at night to sleep; cause to be assessed | resolved | confirmed | G47.00 | S — Synthetic presenting problem anchored to the documented killing of his family and his years of war; resolved into the diagnosis of post-traumatic stress disorder at the consultation. Not a claim about his real sleep. |
| Post-traumatic stress disorder, chronic, confirmed with the CAPS-5 interview (PCL-5 56 at intake); prolonged grief disorder considered and criteria not met | active | confirmed | F43.12 | S — Synthetic modern diagnosis made at the consultation by current criteria; not a retrospective diagnosis of the historical person. |
| Alcohol use disorder, moderate (four DSM-5-TR criteria): drinking at night to sleep, more than intended, unable to cut down, and a fall walking home after drinking; AUDIT 19; liver tests show the pattern of heavy drinking | active | confirmed | F10.20 | S — Synthetic modern diagnosis anchored to his own statement that he was twice jailed for drinking whisky as a prisoner of war; not a claim about his real drinking. |
| A fall in the past month while walking home at night after drinking: bruised left hip, no fracture on examination; Timed Up and Go 13 seconds | active | confirmed | Z91.81 | S — Synthetic fall-risk finding; it is not his documented last fall, which is history after the episode. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PTSD symptom severity (PCL-5) | Baseline, then every visit during treatment | Completed today | 46, from 56 |
| Self-management | Trauma-focused psychotherapy (cognitive processing therapy), sessions attended | Weekly for twelve sessions | Completed today | Four of twelve sessions attended |
| Survey | Depressive symptoms (PHQ-9) | Baseline, then monthly during active treatment | Completed today | 10, from 11; item 9 scored 0 |
| Survey | Suicide-risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; 988 card carried; sertraline dispensed four weeks at a time |
| Self-management | Drinking since the last visit, against his own goal | Every visit | Completed today | Two evenings a week, two drinks each |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | Before starting, at four to six weeks, then every three to six months | Completed today | AST 41, ALT 31, GGT 84 U/L, four weeks on naltrexone |
| Laboratory | PEth, a blood marker of drinking over the past two to four weeks | At baseline and every one to three months during treatment, with consent | Up to date | Due at the next visit |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | Every visit | Completed today | No opioid use; no nausea |
| Medication safety | SSRI safety: sodium, bleeding, falls and side effects | Sodium within the first month in older adults; review at each dose change | Ordered | Sertraline 25 mg started today; sodium due in two to four weeks |
| Medication safety | Prazosin for nightmares | When nightmares persist despite first-line treatment | Not indicated | Not started now: orthostatic falls risk in a man of 77 who fell recently; reconsider after therapy and sertraline |
| Examination | Falls and gait (Timed Up and Go), orthostatic blood pressure | At intake and every visit after a fall | Completed today | Timed Up and Go 12 seconds; standing pressure 130/76; no falls |
| Self-management | Traditional healing alongside clinic care, at his choice | Every visit | Completed today | His choice; nothing asked |
Goal progress:
Guideline basis: VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023); Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults (2017); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Special General Memorandum 94-08: Statement of Policy for the Traditional Cultural Advocacy Program (1994); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024)
Follow-up: Sodium in two to four weeks. Eleven-week review with PEth and liver tests. Therapy weekly. Call the clinic or 988 at any hour. Next scheduled visit 1906-09-23: eleven-week review: therapy progress, sertraline and sodium, drinking and falls. [S]